Market context
Follow the story. See which markets it affects. Explore the context.
Incyte has outperformed the S&P 500 year-to-date, driven by strong sales of Jakafi and Opzelura alongside positive regulatory progress. However, near-term EPS estimates face pressure from acquisition…
The biotech sector is staging a major comeback, outperforming the broader S&P 500 driven by AI-powered drug development, oncology breakthroughs, and industry consolidation. Attractive valuations and …
UnitedHealth Group's corporate profile details its 390,000-person global workforce, recent cost-cutting layoffs, and operational restructuring. After lowering revenue targets earlier in 2026, the hea…
XLV, a healthcare ETF, is criticized for a low dividend yield due to its cap-weighted structure heavily favoring low-yielding Eli Lilly. For significantly higher income, investors are advised to dire…
IRIDEX reported wider Q2 net losses of $1.3 million on a 7% revenue drop to $12.6 million due to weak retina sales, despite strong glaucoma probe demand. The company reaffirmed its full-year 2026 rev…
Glaukos Corporation demonstrates robust growth driven by rapid adoption of its iDose TR and Epioxa platforms, raising 2026 revenue guidance. However, ongoing Medicare reimbursement uncertainties and …
The Cooper Companies (COO) gained 22.2% over three months, driven by strong contact lens market share and recovering fertility revenues. Despite 10 consecutive quarters of beating estimates, near-ter…
Healthcare stocks (LLY, JNJ, ABBV) trail S&P 500's YTD gains despite strong earnings and dividend growth. Sector rotation into defensives and healthcare undervaluation flagged as H2 opportunity, thou…
Eli Lilly posted 48% revenue growth in Q2 2026, driven by MOUNJARO/ZEPBOUND sales of $14.9B, and raised full-year guidance. Strong obesity drug demand and pipeline progress signal continued sector st…
Merck slashed 2026 EPS guidance due to one-time acquisition charges from Terns and Cidara deals, but raised full-year sales outlook. Q2 revenue beat estimates and Keytruda, Winrevair, Capvaxive poste…
AbbVie shares rose 2.9% while the S&P 500 fell 1.0%, driven by strong immunology drug sales and pipeline progress. The stock's low correlation to the broader market highlights its diversification val…
Intraday moves: Abbott down 0.51%, AbbVie up 0.59%, Cardinal Health up 3.93%. No Nvidia-related news or chip-sector catalyst is mentioned.
Market snapshot: ETNB +85.15%, LLY +0.37%, EL +1.59%, RO unchanged. No Meta-related news or catalysts mentioned, leaving META unaffected.